Does Insurance Cover GLP-1 Medication?
A complete guide to Medicare, Medicaid, and private insurance coverage for GLP-1 weight loss medications in 2026. Find out what your plan covers and how to get approved.
Medicare Part D Now Covers GLP-1 Medications
For the first time, Medicare Part D will cover anti-obesity medications for weight loss. This is a major shift that makes GLP-1 treatment accessible to millions of Medicare beneficiaries.
Starting July 1, 2026
Coverage begins mid-year for all Medicare Part D plans nationwide
$50/Month Copay
Maximum out-of-pocket cost for covered GLP-1 medications under Part D
Wegovy & Zepbound Covered
Both semaglutide (Wegovy) and tirzepatide (Zepbound) are included
BMI 30+ or 27+ with Comorbidities
Eligibility requires BMI of 30 or higher, or 27+ with weight-related conditions
How to Get Medicare Part D Coverage
Check your Medicare card or call 1-800-MEDICARE to verify your Part D enrollment. Medicare Advantage plans with drug coverage (MA-PD) also qualify.
Schedule an appointment with your primary care provider or a weight management specialist. They will evaluate whether a GLP-1 medication is appropriate based on your BMI and health history.
Your prescribing physician submits the prescription and any required prior authorization to your Part D plan. Once approved, you can fill your prescription at a participating pharmacy.
State-by-State Medicaid Coverage
Medicaid coverage for GLP-1 weight loss medications varies significantly by state. Some states cover these medications for obesity treatment, while others limit coverage to Type 2 diabetes only. Use the filters below to find your state.
Showing 51 of 51 states
| State | Status | Notes |
|---|---|---|
| Alabama | Not Covered | Alabama Medicaid does not cover GLP-1 medications for obesity; coverage is limited to Type 2 diabetes management with strict criteria. |
| Alaska | Prior Authorization Required | Denali KidCare and Alaska Medicaid cover GLP-1 drugs for Type 2 diabetes with prior authorization, but obesity coverage remains limited. |
| Arizona | Prior Authorization Required | Arizona Health Care Cost Containment System (AHCCCS) covers GLP-1 agonists for diabetes with prior authorization; weight-loss indications require additional review. |
| Arkansas | Not Covered | Arkansas Medicaid covers GLP-1 medications only for Type 2 diabetes management and does not provide coverage for obesity treatment. |
| California | Covered | Medi-Cal covers GLP-1 medications including semaglutide for both Type 2 diabetes and obesity treatment, with prior authorization required for weight management indications. |
| Colorado | Covered | Colorado Medicaid (Health First Colorado) covers GLP-1 agonists for eligible members with Type 2 diabetes and obesity, subject to prior authorization and BMI criteria. |
| Connecticut | Covered | HUSKY Health (Connecticut Medicaid) covers GLP-1 medications for diabetes and has expanded coverage for obesity treatment with prior authorization requirements. |
| Delaware | Prior Authorization Required | Delaware Medicaid covers GLP-1 agonists for Type 2 diabetes with prior authorization; obesity-specific coverage requires documentation of comorbidities. |
| District of Columbia | Covered | DC Medicaid covers GLP-1 medications for both diabetes and obesity management with prior authorization, reflecting the district's expanded Medicaid benefit package. |
| Florida | Not Covered | Florida Medicaid (Statewide Medicaid Managed Care) does not cover GLP-1 drugs for weight loss; coverage is restricted to Type 2 diabetes with prior authorization. |
| Georgia | Not Covered | Georgia Medicaid covers GLP-1 agonists only for Type 2 diabetes management; the state has not expanded coverage to obesity treatment indications. |
| Hawaii | Covered | Med-QUEST (Hawaii Medicaid) covers GLP-1 medications for diabetes and has provisions for obesity treatment coverage with prior authorization for qualifying members. |
| Idaho | Not Covered | Idaho Medicaid covers GLP-1 drugs for Type 2 diabetes only and does not currently extend coverage to obesity or weight management indications. |
| Illinois | Covered | Illinois Medicaid covers GLP-1 agonists for both Type 2 diabetes and obesity treatment, with prior authorization required and BMI thresholds for weight-loss indications. |
| Indiana | Prior Authorization Required | Indiana Medicaid (Healthy Indiana Plan) covers GLP-1 medications for diabetes with prior authorization; obesity coverage is limited and requires physician documentation. |
| Iowa | Prior Authorization Required | Iowa Medicaid covers GLP-1 agonists for Type 2 diabetes with prior authorization; weight management coverage is under ongoing review by the Iowa Department of Health and Human Services. |
| Kansas | Not Covered | KanCare (Kansas Medicaid) limits GLP-1 coverage to Type 2 diabetes management and does not include obesity as a covered indication. |
| Kentucky | Prior Authorization Required | Kentucky Medicaid (Medicaid Managed Care) covers GLP-1 medications for diabetes with prior authorization; obesity coverage eligibility varies by managed care organization. |
| Louisiana | Prior Authorization Required | Louisiana Medicaid covers GLP-1 drugs for Type 2 diabetes with prior authorization and is evaluating expanded coverage for obesity treatment given the state's high obesity rates. |
| Maine | Covered | Maine Medicaid (MaineCare) covers GLP-1 agonists for both diabetes and obesity treatment with prior authorization following the state's full Medicaid expansion. |
| Maryland | Covered | Maryland Medicaid covers GLP-1 medications for Type 2 diabetes and has extended coverage to obesity treatment with prior authorization and BMI criteria. |
| Massachusetts | Covered | MassHealth covers GLP-1 agonists for both diabetes management and obesity treatment, making it one of the more comprehensive state Medicaid programs for weight-loss drugs. |
| Michigan | Prior Authorization Required | Michigan Medicaid (Healthy Michigan Plan) covers GLP-1 drugs for Type 2 diabetes with prior authorization; obesity coverage is available for members meeting specific BMI and comorbidity criteria. |
| Minnesota | Covered | Minnesota Medical Assistance covers GLP-1 agonists for diabetes and has approved obesity treatment coverage with prior authorization for eligible enrollees. |
| Mississippi | Not Covered | Mississippi Medicaid covers GLP-1 medications only for Type 2 diabetes; the state has not expanded Medicaid and does not cover these drugs for obesity treatment. |
| Missouri | Prior Authorization Required | Missouri HealthNet covers GLP-1 agonists for Type 2 diabetes with prior authorization; obesity coverage was not included following the state's 2021 Medicaid expansion. |
| Montana | Prior Authorization Required | Montana Medicaid (Healthy Montana Kids Plus) covers GLP-1 medications for diabetes with prior authorization; obesity coverage is limited under the current benefit structure. |
| Nebraska | Prior Authorization Required | Nebraska Medicaid covers GLP-1 drugs for Type 2 diabetes with prior authorization; obesity-specific coverage is not currently included in the Nebraska Heritage Health benefit package. |
| Nevada | Prior Authorization Required | Nevada Medicaid covers GLP-1 agonists for diabetes with prior authorization and is actively reviewing expanded obesity coverage following the state's full Medicaid expansion. |
| New Hampshire | Prior Authorization Required | NH Medicaid (Granite Advantage Health Care Program) covers GLP-1 medications for diabetes with prior authorization; obesity treatment coverage requires meeting clinical criteria. |
| New Jersey | Covered | NJ FamilyCare covers GLP-1 agonists for both Type 2 diabetes and obesity, with prior authorization required and clinical criteria including BMI thresholds for weight-loss indications. |
| New Mexico | Covered | New Mexico Medicaid (Centennial Care) covers GLP-1 medications for diabetes and obesity treatment with prior authorization for qualifying enrollees. |
| New York | Covered | New York Medicaid covers GLP-1 agonists including semaglutide for both diabetes and obesity treatment, with prior authorization required for weight management indications. |
| North Carolina | Prior Authorization Required | NC Medicaid covers GLP-1 drugs for Type 2 diabetes with prior authorization; following the 2023 Medicaid expansion, the state is evaluating obesity treatment coverage. |
| North Dakota | Prior Authorization Required | North Dakota Medicaid covers GLP-1 agonists for diabetes with prior authorization; obesity-specific coverage is not part of the current ND Medicaid benefit structure. |
| Ohio | Prior Authorization Required | Ohio Medicaid covers GLP-1 medications for Type 2 diabetes with prior authorization; obesity coverage is available under select managed care plans with clinical documentation. |
| Oklahoma | Prior Authorization Required | SoonerCare (Oklahoma Medicaid) covers GLP-1 agonists for diabetes with prior authorization following the state's 2021 Medicaid expansion; obesity coverage is limited. |
| Oregon | Covered | Oregon Health Plan covers GLP-1 medications for both Type 2 diabetes and obesity treatment, with prior authorization required and criteria based on BMI and comorbidities. |
| Pennsylvania | Prior Authorization Required | Pennsylvania Medicaid (MA Program) covers GLP-1 agonists for diabetes with prior authorization; obesity treatment coverage eligibility depends on the managed care organization. |
| Rhode Island | Covered | Rhode Island Medicaid (Medicaid) covers GLP-1 medications for diabetes and obesity with prior authorization, reflecting the state's comprehensive Medicaid expansion benefit package. |
| South Carolina | Not Covered | South Carolina Healthy Connections (Medicaid) covers GLP-1 drugs for Type 2 diabetes only and does not include obesity as a covered treatment indication. |
| South Dakota | Prior Authorization Required | South Dakota Medicaid covers GLP-1 agonists for diabetes with prior authorization; obesity-specific coverage is not currently part of the state's Medicaid formulary. |
| Tennessee | Not Covered | TennCare covers GLP-1 medications for Type 2 diabetes management only; obesity treatment is not a covered indication under the current TennCare benefit package. |
| Texas | Not Covered | Texas Medicaid does not cover GLP-1 drugs for obesity; coverage is restricted to Type 2 diabetes with prior authorization, and the state has not expanded Medicaid. |
| Utah | Prior Authorization Required | Utah Medicaid covers GLP-1 agonists for Type 2 diabetes with prior authorization; obesity coverage is limited under the state's partial Medicaid expansion (Utah Medicaid Expansion). |
| Vermont | Covered | Vermont Medicaid (Green Mountain Care) covers GLP-1 medications for both diabetes and obesity with prior authorization, consistent with the state's expansive Medicaid benefit philosophy. |
| Virginia | Prior Authorization Required | Virginia Medicaid (Cardinal Care) covers GLP-1 drugs for Type 2 diabetes with prior authorization; obesity coverage is available under select managed care plans following the 2019 Medicaid expansion. |
| Washington | Covered | Apple Health (Washington Medicaid) covers GLP-1 agonists including semaglutide for both Type 2 diabetes and obesity treatment with prior authorization and clinical criteria. |
| West Virginia | Prior Authorization Required | West Virginia Medicaid covers GLP-1 medications for diabetes with prior authorization; obesity coverage is under review given the state's high rates of obesity and diabetes. |
| Wisconsin | Prior Authorization Required | BadgerCare Plus (Wisconsin Medicaid) covers GLP-1 agonists for Type 2 diabetes with prior authorization; obesity-specific coverage is not included in the current benefit structure. |
| Wyoming | Not Covered | Wyoming Medicaid covers GLP-1 drugs for Type 2 diabetes management only; the state has not expanded Medicaid and does not cover these medications for obesity treatment. |
Alabama Medicaid does not cover GLP-1 medications for obesity; coverage is limited to Type 2 diabetes management with strict criteria.
Denali KidCare and Alaska Medicaid cover GLP-1 drugs for Type 2 diabetes with prior authorization, but obesity coverage remains limited.
Arizona Health Care Cost Containment System (AHCCCS) covers GLP-1 agonists for diabetes with prior authorization; weight-loss indications require additional review.
Arkansas Medicaid covers GLP-1 medications only for Type 2 diabetes management and does not provide coverage for obesity treatment.
Medi-Cal covers GLP-1 medications including semaglutide for both Type 2 diabetes and obesity treatment, with prior authorization required for weight management indications.
Colorado Medicaid (Health First Colorado) covers GLP-1 agonists for eligible members with Type 2 diabetes and obesity, subject to prior authorization and BMI criteria.
HUSKY Health (Connecticut Medicaid) covers GLP-1 medications for diabetes and has expanded coverage for obesity treatment with prior authorization requirements.
Delaware Medicaid covers GLP-1 agonists for Type 2 diabetes with prior authorization; obesity-specific coverage requires documentation of comorbidities.
DC Medicaid covers GLP-1 medications for both diabetes and obesity management with prior authorization, reflecting the district's expanded Medicaid benefit package.
Florida Medicaid (Statewide Medicaid Managed Care) does not cover GLP-1 drugs for weight loss; coverage is restricted to Type 2 diabetes with prior authorization.
Georgia Medicaid covers GLP-1 agonists only for Type 2 diabetes management; the state has not expanded coverage to obesity treatment indications.
Med-QUEST (Hawaii Medicaid) covers GLP-1 medications for diabetes and has provisions for obesity treatment coverage with prior authorization for qualifying members.
Idaho Medicaid covers GLP-1 drugs for Type 2 diabetes only and does not currently extend coverage to obesity or weight management indications.
Illinois Medicaid covers GLP-1 agonists for both Type 2 diabetes and obesity treatment, with prior authorization required and BMI thresholds for weight-loss indications.
Indiana Medicaid (Healthy Indiana Plan) covers GLP-1 medications for diabetes with prior authorization; obesity coverage is limited and requires physician documentation.
Iowa Medicaid covers GLP-1 agonists for Type 2 diabetes with prior authorization; weight management coverage is under ongoing review by the Iowa Department of Health and Human Services.
KanCare (Kansas Medicaid) limits GLP-1 coverage to Type 2 diabetes management and does not include obesity as a covered indication.
Kentucky Medicaid (Medicaid Managed Care) covers GLP-1 medications for diabetes with prior authorization; obesity coverage eligibility varies by managed care organization.
Louisiana Medicaid covers GLP-1 drugs for Type 2 diabetes with prior authorization and is evaluating expanded coverage for obesity treatment given the state's high obesity rates.
Maine Medicaid (MaineCare) covers GLP-1 agonists for both diabetes and obesity treatment with prior authorization following the state's full Medicaid expansion.
Maryland Medicaid covers GLP-1 medications for Type 2 diabetes and has extended coverage to obesity treatment with prior authorization and BMI criteria.
MassHealth covers GLP-1 agonists for both diabetes management and obesity treatment, making it one of the more comprehensive state Medicaid programs for weight-loss drugs.
Michigan Medicaid (Healthy Michigan Plan) covers GLP-1 drugs for Type 2 diabetes with prior authorization; obesity coverage is available for members meeting specific BMI and comorbidity criteria.
Minnesota Medical Assistance covers GLP-1 agonists for diabetes and has approved obesity treatment coverage with prior authorization for eligible enrollees.
Mississippi Medicaid covers GLP-1 medications only for Type 2 diabetes; the state has not expanded Medicaid and does not cover these drugs for obesity treatment.
Missouri HealthNet covers GLP-1 agonists for Type 2 diabetes with prior authorization; obesity coverage was not included following the state's 2021 Medicaid expansion.
Montana Medicaid (Healthy Montana Kids Plus) covers GLP-1 medications for diabetes with prior authorization; obesity coverage is limited under the current benefit structure.
Nebraska Medicaid covers GLP-1 drugs for Type 2 diabetes with prior authorization; obesity-specific coverage is not currently included in the Nebraska Heritage Health benefit package.
Nevada Medicaid covers GLP-1 agonists for diabetes with prior authorization and is actively reviewing expanded obesity coverage following the state's full Medicaid expansion.
NH Medicaid (Granite Advantage Health Care Program) covers GLP-1 medications for diabetes with prior authorization; obesity treatment coverage requires meeting clinical criteria.
NJ FamilyCare covers GLP-1 agonists for both Type 2 diabetes and obesity, with prior authorization required and clinical criteria including BMI thresholds for weight-loss indications.
New Mexico Medicaid (Centennial Care) covers GLP-1 medications for diabetes and obesity treatment with prior authorization for qualifying enrollees.
New York Medicaid covers GLP-1 agonists including semaglutide for both diabetes and obesity treatment, with prior authorization required for weight management indications.
NC Medicaid covers GLP-1 drugs for Type 2 diabetes with prior authorization; following the 2023 Medicaid expansion, the state is evaluating obesity treatment coverage.
North Dakota Medicaid covers GLP-1 agonists for diabetes with prior authorization; obesity-specific coverage is not part of the current ND Medicaid benefit structure.
Ohio Medicaid covers GLP-1 medications for Type 2 diabetes with prior authorization; obesity coverage is available under select managed care plans with clinical documentation.
SoonerCare (Oklahoma Medicaid) covers GLP-1 agonists for diabetes with prior authorization following the state's 2021 Medicaid expansion; obesity coverage is limited.
Oregon Health Plan covers GLP-1 medications for both Type 2 diabetes and obesity treatment, with prior authorization required and criteria based on BMI and comorbidities.
Pennsylvania Medicaid (MA Program) covers GLP-1 agonists for diabetes with prior authorization; obesity treatment coverage eligibility depends on the managed care organization.
Rhode Island Medicaid (Medicaid) covers GLP-1 medications for diabetes and obesity with prior authorization, reflecting the state's comprehensive Medicaid expansion benefit package.
South Carolina Healthy Connections (Medicaid) covers GLP-1 drugs for Type 2 diabetes only and does not include obesity as a covered treatment indication.
South Dakota Medicaid covers GLP-1 agonists for diabetes with prior authorization; obesity-specific coverage is not currently part of the state's Medicaid formulary.
TennCare covers GLP-1 medications for Type 2 diabetes management only; obesity treatment is not a covered indication under the current TennCare benefit package.
Texas Medicaid does not cover GLP-1 drugs for obesity; coverage is restricted to Type 2 diabetes with prior authorization, and the state has not expanded Medicaid.
Utah Medicaid covers GLP-1 agonists for Type 2 diabetes with prior authorization; obesity coverage is limited under the state's partial Medicaid expansion (Utah Medicaid Expansion).
Vermont Medicaid (Green Mountain Care) covers GLP-1 medications for both diabetes and obesity with prior authorization, consistent with the state's expansive Medicaid benefit philosophy.
Virginia Medicaid (Cardinal Care) covers GLP-1 drugs for Type 2 diabetes with prior authorization; obesity coverage is available under select managed care plans following the 2019 Medicaid expansion.
Apple Health (Washington Medicaid) covers GLP-1 agonists including semaglutide for both Type 2 diabetes and obesity treatment with prior authorization and clinical criteria.
West Virginia Medicaid covers GLP-1 medications for diabetes with prior authorization; obesity coverage is under review given the state's high rates of obesity and diabetes.
BadgerCare Plus (Wisconsin Medicaid) covers GLP-1 agonists for Type 2 diabetes with prior authorization; obesity-specific coverage is not included in the current benefit structure.
Wyoming Medicaid covers GLP-1 drugs for Type 2 diabetes management only; the state has not expanded Medicaid and does not cover these medications for obesity treatment.
Private Insurance Coverage
Most major private insurance carriers cover GLP-1 medications for Type 2 diabetes, and an increasing number now cover weight loss indications. Coverage varies by plan and employer, so check with your specific carrier for details.
Aetna
Aetna covers GLP-1 medications for Type 2 diabetes on most plans. Weight loss coverage varies by employer-sponsored plan and typically requires prior authorization with documented BMI criteria.
UnitedHealthcare
UnitedHealthcare covers semaglutide and tirzepatide for diabetes management. Obesity coverage depends on the specific plan, with many employer plans adding weight loss benefits in 2025-2026.
Blue Cross Blue Shield
BCBS coverage varies significantly by state and plan. Many BCBS affiliates cover GLP-1 medications for diabetes, with an increasing number of plans adding obesity treatment coverage.
Cigna
Cigna covers GLP-1 agonists for Type 2 diabetes on most commercial plans. Weight management coverage is available on select employer-sponsored plans with prior authorization requirements.
Humana
Humana covers GLP-1 medications for diabetes on Medicare Advantage and commercial plans. Weight loss coverage is expanding across Humana plans, particularly for members with BMI 30+ or comorbidities.
Kaiser Permanente
Kaiser Permanente covers GLP-1 medications for both diabetes and weight management for eligible members. Coverage typically includes integrated care with dietary counseling and lifestyle programs.
Coverage details vary by specific plan, employer, and state. Contact your insurance carrier directly or check your plan documents for exact coverage terms and formulary details.
How to Get Coverage Approved
Prior Authorization Steps
Schedule a visit with your doctor to discuss GLP-1 medication and document your BMI, weight history, and any weight-related health conditions.
Your doctor submits a prior authorization request to your insurance plan with clinical documentation including BMI, previous weight loss attempts, and comorbidities.
The insurance company reviews the request, typically within 5-15 business days. Some plans offer expedited review for urgent cases.
If approved, your doctor receives confirmation and sends the prescription to your pharmacy. If denied, you can begin the appeals process.
What to Do If Your Claim Is Denied
Request a written explanation of the denial from your insurance company, including the specific reason and the clinical criteria they used to make the decision.
Ask your doctor to write a letter of medical necessity explaining why GLP-1 treatment is clinically appropriate for you, citing your BMI, comorbidities, and failed prior weight loss attempts.
File a formal appeal with your insurance company within the required timeframe (usually 30-180 days depending on the plan). Include your doctor's letter and all supporting documentation.
If the internal appeal is denied, you have the right to an external review by an independent third party. Your insurance company is required to inform you of this option.
Savings Programs as a Fallback
Novo Nordisk and Eli Lilly offer savings programs that can reduce costs to as low as $0-$25/month for commercially insured patients. These programs are not available for Medicare or Medicaid beneficiaries.
Compounding pharmacies offer semaglutide and tirzepatide at significantly lower prices ($150-$500/month). These do not require insurance approval but should be obtained through a licensed provider. Find a provider near you.
Both Novo Nordisk (for Wegovy/Ozempic) and Eli Lilly (for Mounjaro/Zepbound) offer patient assistance programs for uninsured or underinsured individuals who meet income eligibility requirements.
Find a GLP-1 Provider Near You
Whether you have insurance coverage or need an affordable alternative, our directory lists 9,500+ verified GLP-1 clinics across all 50 states with real pricing and insurance information.